Ongoing Clinical Trials
Currently open in Europe, this trial in patients with HCC and ICC will assess the safety and efficacy of Melphalan/HDS. The trial will also evaluate overall response rate via (mRECIST) criteria, progression free survival, characterize the systemic exposure of melphalan and assess patient quality of life. Three hospitals in Germany have opened for enrollment --- Goethe University Hospital, Hannover Medical School Hospital and Jena University Hospital. Additional centers in Germany, the U.K.and Italy are in the process of being opened subject to the applicable authorizations and approvals including ethics committee approval at participating hospitals.
Clinical Trials As part of its mission to make a clinically meaningful difference for patients with cancers of the liver, Delcath Systems is deeply committed to the clinical development of Percutaneous Hepatic Perfusion (PHP)*. To date, PHP has been the subject of peer-reviewed papers, as well as multiple oral and poster presentations. Additional trials are underway to examine the use of PHP in metastatic ocular melanoma, as well as primary liver cancer (HCC/ICC). * For Investigational Use Only in the U.S.
Delcath does not make any claim whatsoever, real or implied, about the efficacy or safety of any therapy, drug, system, or technique under active research.